RAC 5.44% $1.65 race oncology ltd

Looking at the original document, MST's RAC valuation appears to...

  1. 352 Posts.
    lightbulb Created with Sketch. 799
    Looking at the original document, MST's RAC valuation appears to be done on an undiluted basis. Back in February 2021, RAC had 129.5 million shares on issue. At a price of $4.88 per share, that gave RAC an undiluted valuation of $632 million.

    As of 11 March 2022, RAC had 159.5 million shares on issue, so at $4.16 per share, MST would appear to have increased their undiluted valuation of RAC to $663.5 million (exactly a 5% increase since Feb 2021).

    So the drop in per-share valuation is not quite as bad as it appears at first glance. Though just giving a 5% increase without seeing the justification behind it would seem to be somewhat arbitrary... e.g. maybe they just gave us a CPI increase.

    Also, I have no doubt that RAC management would feel (as do many of us I'm sure) that the progress and discoveries made since February last year would warrant much more than a 5% increase and that could easily explain any pre-presentation tension if that were the case.
    Last edited by KingBuzzo: 22/03/22
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.